



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Octahydrocurcumin

Cat. No.:	HY-N0894
CAS No.:	36062-07-4
Molecular Formula:	C ₂₁ H ₂₈ O ₆
Molecular Weight:	376.44
Target:	Reactive Oxygen Species
Pathway:	Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Storage:	Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (265.65 mM; Need ultrasonic)
Ethanol : 10 mg/mL (26.56 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.6565 mL	13.2823 mL	26.5647 mL
	5 mM		0.5313 mL	2.6565 mL	5.3129 mL
	10 mM		0.2656 mL	1.3282 mL	2.6565 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 3.75 mg/mL (9.96 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 3.75 mg/mL (9.96 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 3.75 mg/mL (9.96 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Octahydrocurcumin is a hydrogenated derivatives of curcumin; metabolite of curcumin. IC50 value: Target: OKT3-induced PBMC proliferation was inhibited by octahydrocurcumin with IC50 of 82 uM. The investigated substances with the strongest effect on radical scavenging were tetrahydro-, hexahydro-, and octahydrocurcumin with IC50 values of 10.0, 11.7, and 12.3 microM, respectively [1]. curcumin and tetrahydrocurcumin significantly inhibited the release of prominent cytokines, including tumor necrosis factor α (TNF α) and interleukin 6 (IL 6); however, hexahydrocurcumin and octahydrocurcumin did not significantly alter cytokine release [2]. Hydrogenated derivatives of curcumin exhibited stronger DPPH scavenging

activity compared to curcumin and a reference antioxidant, trolox. The scavenging activity significantly decreased in the order $\text{THC} > \text{HHC} = \text{OHC} > \text{trolox} > \text{curcumin} > \text{Dmc} > \text{Bdmc}$ [3].

REFERENCES

- [1]. Deters M, et al. Different curcuminoids inhibit T-lymphocyte proliferation independently of their radical scavenging activities. *Pharm Res.* 2008 Aug;25(8):1822-7.
- [2]. Zhao F, et al. Curcumin and its major metabolites inhibit the inflammatory response induced by lipopolysaccharide: Translocation of nuclear factor- κ B as potential target. *Mol Med Rep.* 2015 Apr;11(4):3087-93.
- [3]. Somparn P, et al. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. *Biol Pharm Bull.* 2007 Jan;30(1):74-8.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA